US Communications Director

Henlius USA Inc.; New Jersey; On-site; USD 150,000 - 210,000; Full time

Job summary

Henlius USA Inc. seeks a strategic, hands-on US Communications Director to lead corporate and launch communications for the US market.

You will report to a senior leader at our China headquarters and execute key communications initiatives as an individual contributor. You will work cross-functionally with commercial, marketing, medical, regulatory, market access, investor relations and other teams to shape Henlius’ external narrative in the US.

Qualifications

• Bachelor’s degree in Communications, Public Relations, Journalism, Marketing, or related field required.
• 7+ years of experience in biopharma/healthcare communications or corporate affairs.
• Experience launching products and managing corporate communications initiatives.
• Strong understanding of US healthcare/pharma environments, including biosimilars.

Responsibilities

• Develop and execute corporate and launch communications strategies to build brand presence in the US healthcare/biotech ecosystem.
• Create launch materials: press releases, messaging, Q&A, talking points, and other materials.
• Manage media relations and opportunities, including conferences and executive visibility.
• Support near-term launch readiness and day-one communications.
• Oversee external agencies for media, digital, website and social initiatives.

Skills

Strategic communications

Media relations

Public relations

Corporate communications

Writing

Stakeholder management

Project management

Education

Bachelor’s degree in Communications, Public Relations, Journalism, Marketing, or related field

Advanced degree preferred

Job description

Here at Henlius, we are seeking a strategic, hands-on US Communications Director to support our upcoming commercial launch in the US market and ongoing needs. Reporting to a dynamic senior leader at our China Headquarter, this role will lead US corporate and communications strategy while also serving as an individual contributor responsible for hands-on execution of key communications initiatives.

This is a highly visible, matrixed role that will work cross-functionally with numerous internal stakeholders (commercial, marketing, medical, regulatory, market access, investor relations, etc) to shape Henlius’ external narrative in the US. In the near term, a key priority for this position will be to support launch readiness and launch execution, including Day 1 communications, media engagement, stakeholder visibility, and related brand-building activities. The role will also oversee external agencies and vendors supporting digital, media, and corporate communications activities.

Key Responsibilities

Corporate & Launch Communication

• Develop and execute comprehensive corporate and launch communications strategies to build Henlius’ brand presence and reputation in the US healthcare and biotech ecosystem
• Develop and execute key launch materials, including press releases, messaging, Q&A, executive talking points, and other communication material
• Manage media relations and support speaking opportunities, conferences, and executive visibility and opportunities that support corporate and launch objectives.
• Support near-term commercial launch readiness and execution,
• Manage relationships with key healthcare, biotech, pharmaceutical, and business media.

Product Communication

• Support communications for the bevacizumab biosimilar launch and future pipeline products.
• Partner cross-functionally with commercial marketing, medical, regulatory, and market access teams to ensure aligned and compliant messaging.
• Develop external-facing content such as healthcare professionals, patients and stakeholders and monitor market, competitive, and industry developments.
• Manage external agencies and vendors supporting media, digital, website, and social media initiatives.
• Oversee website content updates and vendor-led social media execution.
• Review deliverables to ensure quality, consistency, and alignment with company objectives.

Stakeholder Engagement & Global Coordination

• Build relationships with media, KOLs, patient advocacy groups, industry associations, and other key external stakeholders.
• Support investor relations, issues management, and corporate reputation initiatives as needed.
• Partner closely with China HQ and internal cross-functional teams to align messaging, approvals, and launch communications across markets and time zones.
• Manage crisis communication & reputation management

Requirements

• Bachelor’s degree in Communications, Public Relations, Journalism, Marketing, or a related field; advanced degree preferred.
• 7+ years of experience required.
• Experience in communications, public relations, or corporate affairs in biotechnology, pharmaceuticals, healthcare, or a related field.
• Demonstrated experience supporting product launch and corporate communications initiatives.
• Strong understanding of the US healthcare and pharmaceutical environment, including biosimilars.
• Excellent writing, communication, and project management skills.
• Proven media relations experience and experience managing external vendors or agencies.
• Ability to work effectively across cross-functional and global teams in a matrixed organization.
• Willingness to operate as an individual contributor with hands-on execution responsibility.

Preferred Qualifications

• Experience in biosimilar, oncology, or specialty pharmaceutical communications.
• Experience supporting US commercial launch communications.
• Experience working with global teams and/or reporting into an international headquarters structure, including China HQ.
• Crisis communications or issues management experience.
• Combination of agency and in-house communications experience.
• Familiarity with FDA and other relevant pharmaceutical communications regulations.
• Experience overseeing website, digital, and social media communications.

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 10 products have been approved for marketing worldwide, and 5 marketing applications have been accepted for review in China and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANLIKANG (rituximab), the first China-developed biosimilar, denosumab Bildyos® and Bilprevda®. and pertuzumab Poherdy®. What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.

For more information, please visit https://www.henlius.com/en/Index.html